Gastrointestinal Cancer News

Results of a large cohort nationwide study in The Netherlands have shown that risk for colorectal cancer was not increased for patients that had ovarian stimulation with in-vitro fertilization compared to the general population; however, the risk was found to be higher in these patients, compared to patients that underwent other subfertility treatments.

SAN FRANCISCO — First-line treatment with modified FOLFOX7 or modified FOLFIRI chemotherapy resulted in comparable progression-free survival and disease control rate among patients with locally advanced gastric adenocarcinoma, while a subgroup of patients who received mFOLFOX7 followed by mFOLFIRI had better overall survival, according to phase 2 study results presented at the Gastrointestinal Cancers Symposium.

SAN FRANCISCO — Gary W. Falk, MD, from the University of Pennsylvania Perelman School of Medicine and the Abramson Cancer Center, discusses his talk as part of a debate about screening for Barrett’s esophagus and esophageal adenocarcinoma, which he delivered at the Gastrointestinal Cancers Symposium.

The lack of caudal-type homeobox transcription factor 2 expression identified patients with high-risk stage II colon cancer who benefited from adjuvant chemotherapy, according to research published in The New England Journal of Medicine.

In the MORE clinical trial, the use of SIR-Spheres ytrrium-90 resin microspheres for radioembolization was safe and effective among elderly patients with unresectable liver-dominant metastatic colorectal cancer.

HemOnc Today’s Chief Medical Editors — Derek Raghavan, MD, PhD, and John Sweetenham, MD — discuss the proliferation of guidelines based on expert opinion rather than high-level data. They also highlight the potential for guidelines to create confusion or anxiety among patients, as well as influence payer decisions.

Everolimus appeared to delay the progression of neuroendocrine tumors that originate in the gastrointestinal tract or are of unknown origin, according to results of a subgroup analysis of the RADIANT-4 phase 3 study presented at the Gastrointestinal Cancers Symposium.

A short-course 5-day radiation regimen followed by consolidated chemotherapy prior to surgery appeared as effective as and less toxic than the standard 5-week chemoradiation course for patients with advanced rectal cancer, according to phase 3 study results presented at the Gastrointestinal Cancers Symposium.

Treatment with 177Lutetium-DOTATE appeared to improve the overall response rate and prolonged PFS compared with octreotide among previously treated patients with advanced midgut neuroendocrine tumors, according to early results from the phase 3 NETTER-1 trial presented at the Gastrointestinal Cancers Symposium.

Factors including early hospice enrollment, avoidance of ICU admission within 30 days of death and death occurring outside the hospital appeared associated with favorable perceptions of end-of-life care among family members of older patients who died of cancer, according to the results of an interview-based study published in JAMA.